Applied Molecular holders get 0.174 Cyclo shares in exchange for AMT share

Under the terms of the Merger Agreement, AMT (AMTI) stockholders will receive approximately 0.174 shares of Cyclo (CYTH)Therapeutics in exchange for each of their shares in AMT . Cyclo Therapeutics expects to issue approximately 7.624M shares of Cyclo Therapeutics’ common stock to AMT shareholders, equating to approximately 25% of the combined company on a fully diluted basis. The combined company will be led by the existing Cyclo Therapeutics management team and will be headquartered in Gainesville, FL. Subsequent to the closing of the transaction, Shawn Cross, Chief Executive Officer and Board Chair of AMT will be appointed to the Cyclo Therapeutics Board of Directors.